ScienceDaily (June 13, 2012)  With    their potential to treat a wide range of diseases and uncover    fundamental processes that lead to those diseases, embryonic    stem (ES) cells hold great promise for biomedical science. A    number of hurdles, both scientific and non-scientific, however,    have precluded scientists from reaching the holy grail of using    these special cells to treat heart disease, diabetes,    Alzheimer's and other diseases.  
    In a paper published June 13 in Nature, scientists at    the Salk Institute for Biological Studies report discovering    that ES cells cycle in and out of a "magical state" in the    early stages of embryo development, during which a battery of    genes essential for cell potency (the ability of a generic cell    to differentiate, or develop, into a cell with specialized    functions) is activated. This unique condition, called    totipotency, gives ES cells their unique ability to turn into    any cell type in the body, thus making them attractive    therapeutic targets.  
    "These findings," says senior author Samuel L. Pfaff, a    professor in Salk's Gene Expression Laboratory, "give new    insight into the network of genes important to the    developmental potential of cells. We've identified a mechanism    that resets embryonic stem cells to a more youthful state,    where they are more plastic and therefore potentially more    useful in therapeutics against disease, injury and aging."  
    ES cells are like silly putty that can be induced, under the    right circumstances, to become specialized cells-for example,    skin cells or pancreatic cells-in the body. In the initial    stages of development, when an embryo contains as few as five    to eight cells, the stem cells are totipotent and can develop    into any cell type. After three to five days, the embryo    develops into a ball of cells called a blastocyst. At this    stage, the stem cells are pluripotent, meaning they can develop    into almost any cell type. In order for cells to differentiate,    specific genes within the cells must be turned on.  
    Pfaff and his colleagues performed RNA sequencing (a new    technology derived from genome-sequencing to monitor what genes    are active) on immature mouse egg cells, called oocytes, and    two-cell-stage embryos to identify genes that are turned on    just prior to and immediately following fertilization. Pfaff's    team discovered a sequence of genes tied to this privileged    state of totipotency and noticed that the genes were activated    by retroviruses adjacent to the stem cells.  
    Nearly 8 percent of the human genome is made up of ancient    relics of viral infections that occurred in our ancestors,    which have been passed from generation to generation but are    unable to produce infections. Pfaff and his collaborators found    that cells have used some of these viruses as a tool to    regulate the on-off switches for their own genes. "Evolution    has said, 'We'll make lemonade out of lemons, and use these    viruses to our advantage,'" Pfaff says. Using the remains of    ancient viruses to turn on hundreds of genes at a specific    moment of time in early embryo development gives cells the    ability to turn into any type of tissue in the body.  
    From their observations, the Salk scientists say these viruses    are very tightly controlled-they don't know why-and active only    during a short window during embryonic development. The    researchers identified ES cells in early embryogenesis and then    further developed the embryos and cultured them in a laboratory    dish. They found that a rare group of special ES cells    activated the viral genes, distinguishing them from other ES    cells in the dish. By using the retroviruses to their    advantage, Pfaff says, these rare cells reverted to a more    plastic, youthful state and thus had greater developmental    potential.  
    Pfaff's team also discovered that nearly all ES cells cycle in    and out of this privileged form, a feature of ES cells that has    been underappreciated by the scientific community, says first    author Todd S. Macfarlan, a former postdoctoral researcher in    Pfaff's lab who recently accepted a faculty position at the    Eunice Kennedy Shriver National Institute of Child Health and    Human Development. "If this cycle is prevented from happening,"    he says, "the full range of cell potential seems to be    limited."  
    It is too early to tell if this "magical state" is an opportune    time to harvest ES cells for therapeutic purposes. But, Pfaff    adds, by forcing cells into this privileged status, scientists    might be able to identify genes to assist in expanding the    types of tissue that can be produced.  
    "There's tremendous hype over the practical applications of    embryonic stem cells in clinical situations," he says. "The    struggle in labs throughout the world is that the smallest    changes in environmental conditions could subtly and    unpredictably have an effect on these cells. So, the more we    know about the basic requirements needed for these cells to be    able to generate a full range of tissue types, the better off    we'll be." While the findings shed light on the basic biology    of embryonic stem cells, Pfaff says there is still a "long way    to go" in terms of their practical, clinical value.  
Continued here:
'Magical state' of embryonic stem cells may help overcome hurdles to therapeutics